The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of Cancer Research: Royal Cancer Hospital (The) has also partnered on federal grants with The Washington University to adapt medical imaging software platforms, develop annotation frameworks for training cancer detection AI models, and implement support for additional radiotherapy data modalities. These subawards under the DOD's peer reviewed cancer research program support the integration and analysis of multi-parametric data to enable translational cancer research. The award commenced on June 1, 2024 and is set to conclude on May 31, 2027.